Sign in
OABIW Stock Price, Chart, Stats & News
OmniAb, Inc.
Save
251.06M
Market cap
–
Current P/E
–
Forward P/E
OABIW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 73.45% |
Operating margin | -383.15% |
Pretax margin | -342.72% |
Net margin | -347.04% |
Effective tax rate | -1.26% |
ROA | -21.53% |
ROE | -23.99% |
D/E | 0.08x |
Interest coverage ratio | – |
OABIW valuation
P/E | – |
P/S | 9.21x |
P/B | 0.72x |
P/CF | -5.29x |
P/FCF | -4.64x |
P/OCF | -5.29x |
PEG | -1.73x |
EV multiple | -3.74x |
About
OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents.
Similar securities
Based on sector and market capitalization
Report issue